Radiopharmaceutical developer Navidea Biopharmaceuticals is touting clinical results from a study that included the use of its late-stage radiopharmaceutical imaging candidate, AZD4694, for detecting cerebral amyloid in Alzheimer's disease patients.
The study, sponsored by biopharmaceutical company AstraZeneca, was presented at the annual Human Amyloid Imaging (HAI) meeting in Miami. In December 2011, Navidea in-licensed worldwide exclusive rights to AZD4694 from AstraZeneca.
The findings show that AZD4694 PET for detecting cerebral amyloid in Alzheimer's patients is feasible and relatively straightforward with common analysis methodologies, according to Navidea.
The company is making arrangements to start a phase III clinical program in early 2013, and this year it will be conducting further studies to build the requisite safety and training database for AZD4694, it said.
